Industry / Romania
Drug Market Avoids BMI Ratings Downgrade
December 2011 | Industry Trend AnalysisBMI View: Corrections to the reintroduced claw-back mechanism in Romania are favourable to drugmakers, but the levy itself is still overly burdensome. In October 2011, we stated that: 'We are considering an unfavourable downgrade to our industry risk indicator in BMI's Pharmaceuticals & Healthcare Business Environment Ratings (BERs), which would mean the attractiveness of Romania as a destination for drugmakers dropping from third in Central and Eastern Europe (CEE) to seventh.' Due to the favourable amendments in November we will not go ahead with this ratings downgrade.
To read the full article, please choose one of the following options:
Subcribers please log in




